IASO Bio Wins First Prize in Growth Category at 2024 Jiangsu Future Industries Innovation and Entrepreneurship Competition

On August 31, as one of the initiatives to implement Jiangsu Province's policies to accelerate the cultivation and development of future industries, the "2024 Jiangsu Future Industry Innovation and Entrepreneurship Competition" was successfully hosted by Jiangsu High-Tech Investment Group under the guidance of the Jiangsu Development and Reform Commission. IASO Bio,As a leading company in the gene and cell therapy industry, IASO Bio has achieved revolutionary research results — the world's first approved fully human CAR-T product, Equecabtagene Autoleucel Injection (Forcused).^®), standing out among numerous high-quality future industry projects, won the Growth Group First Prize in the competition.! Demonstrates IASO Bio's strong R&D capabilities in the biopharmaceutical field and the immense market potential of its products.

This competition aims to discover and cultivate future industry projects with high technological content, good market prospects, and strong driving effects. It is reported that a total of 125 companies participated in the competition for the Growth Group awards, and IASO Bio was very honored to jointly receive the highest award, the First Prize, with another company.

IASO Bio's Award-Winning Project – Icaritin Injection (Fucosun)^®), which was approved for marketing by the National Medical Products Administration in June 2023, is used to treat adult patients with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy (including at least one proteasome inhibitor and one immunomodulatory agent). It is the world’s first immunocellular therapeutic drug utilizing a fully human antibody sequence and China’s first self-developed and fully independently manufactured immunocellular therapeutic drug. Since its market launch a year ago, Fokosu^®Benefited hundreds of patients in nearly a hundred hospitals across China, while also attracting more than twenty overseas patients to come to China for treatment. In addition to its significant clinical value, because the entire process is independently produced, Fokusu^®It also broke the situation of high dependence on imports for the core raw material, lentiviral vectors.Sets a benchmark for the independent development of China's cell therapy field。